Earlier: Immutep Data From Safety Lead-in Phase of AIPAC-003 Confirmed Complete Response In A Patient With Metastatic Breast Cancer Refractory To Several Lines Of Therapy Achieved During Combination Treatment With 90mg Efti And Paclitaxel
Portfolio Pulse from Charles Gross
Immutep Limited announced positive data from the safety lead-in phase of the AIPAC-003 trial, showing a complete response in a metastatic breast cancer patient using a combination of 90mg efti and paclitaxel.
May 15, 2024 | 9:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited announced positive data from the AIPAC-003 trial, showing a complete response in a metastatic breast cancer patient using 90mg efti and paclitaxel.
The announcement of a complete response in a patient with metastatic breast cancer using Immutep's treatment is a significant milestone. This positive data could boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100